Cellbri Bio

Shenzhen Cellbri Bio-Innovation Technology Co., Ltd, a prominent player in China’s cell and gene therapy (CGT) sector, has reportedly secured nearly RMB 200 million in a Series B financing round. The round was led by 3E Bioventures, with participation from HongSheng Capital and existing investors including Beijing Shuimu Guoding Investment,…